IPP Bureau
Optimus Pharma to manufacture and market molnupiravir
By IPP Bureau - December 28, 2021
The company has developed the API in house at its R&D center in Hyderabad
Covaxin receives approval for Emergency Use in Children 12-18 years
By IPP Bureau - December 27, 2021
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Lupin receives U.S. FDA approval for Sevelamer Carbonate
By IPP Bureau - December 27, 2021
This product will be manufactured at Lupin's Goa facility in India
Roche gets U.S. FDA nod for at-home Covid-19 self-testing solution
By IPP Bureau - December 27, 2021
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Healthcare start-up Zorgers raises angel round
By IPP Bureau - December 27, 2021
The Home Healthcare market is expected to be US $ 14.2 by 2025
U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir
By IPP Bureau - December 24, 2021
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Indian Pharmaceutical Market grew at 6.6 pc in November
By IPP Bureau - December 24, 2021
Flattish volume growth and subdued new launches were key factors for last month
Novavax and SK bioscience expand manufacturing agreement
By IPP Bureau - December 24, 2021
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director
By IPP Bureau - December 24, 2021
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
By IPP Bureau - December 24, 2021
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Lecanemab granted Fast Track designation by the U.S. FDA
By IPP Bureau - December 24, 2021
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
CanSinoBio’s Convidecia vaccine largely effective against Covid-19 in phase III trial
By IPP Bureau - December 24, 2021
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Study shows AstraZeneca’s Covid-19 booster dose protects against Omicron
By IPP Bureau - December 23, 2021
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Pfizer’s Covid-19 pill gets U.S. FDA clearance
By IPP Bureau - December 23, 2021
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Evusheld neutralises Omicron in latest studies
By IPP Bureau - December 23, 2021
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
